TB-500 healing claims: what the peptide science actually supports

What did @sally.swalling actually say?

This video is almost entirely a reconstitution tutorial, not a science explainer. The caption does the heavy lifting on claims, describing TB-500 as designed to "accelerate healing, reduce inflammation, and promote tissue regeneration" by "mimicking natural mechanisms that encourage cell migration." The spoken content is about technique: removing a cap, cleaning with bacteriostatic water, using two millilitres to reconstitute, angling the syringe down the vial wall, rolling rather than shaking. That is the whole video. The claims about what TB-500 actually does live in the caption and hashtags, not the spoken words.

Worth noting: she says "10 lograms" which appears to be a mispronunciation of micrograms or milligrams. Given standard TB-500 vial sizes, she almost certainly means 10 milligrams. That ambiguity matters more than it might seem, because dosing precision with peptides is not trivial.

Does the science back this up?

The caption claims are broadly consistent with the known pharmacology of TB-500, but the evidence base is weaker than the confident language implies. TB-500 is a synthetic version of Thymosin Beta-4 (TB4), a naturally occurring peptide that does play a role in actin sequestration and cell migration. The problem is that most of the compelling data is preclinical.

Chang et al. (2011, Journal of Investigative Dermatology) showed TB4 accelerated wound closure in animal models. Bock-Marquette et al. (2004, Nature) found it promoted cardiac repair in mice after infarction. These are real studies, not cherry-picked. But there are no large-scale randomised controlled trials in humans establishing that exogenous TB-500 administration replicates these effects at the doses typically self-administered. The mechanism claim, that it mimics natural cell migration pathways, is mechanistically plausible but extrapolating from mouse hearts to human injury recovery is a significant leap. The science is interesting. It is not settled.

What did they get wrong (or right)?

On reconstitution technique, she actually gets the fundamentals right. Angling the needle so the bacteriostatic water runs down the side of the vial, rather than blasting it directly onto the lyophilised powder, is the correct approach. It reduces the risk of denaturing the peptide. Rolling rather than shaking is also correct. Shaking creates air bubbles and mechanical stress that can degrade peptide structure. These are small things, but they matter for anyone actually handling this compound.

What is wrong: the caption language is doing marketing work, not science communication. Phrases like "designed to" imply a level of human clinical validation that does not yet exist for TB-500 specifically. TB4 has biological functions, yes. Whether a subcutaneous injection of its synthetic analogue translates those functions into meaningful recovery outcomes in healthy humans is a different and largely unanswered question. The affiliate code and vendor tag make the commercial relationship explicit, which readers should factor into how they weight the enthusiasm.

What should you actually know?

TB-500 is not approved by the TGA in Australia or the FDA in the United States for human use. It is classified as a research chemical in most jurisdictions. That does not make it dangerous by default, but it does mean there is no regulatory quality control on what you are actually injecting, no standardised dosing guidance based on human trials, and no post-market surveillance catching adverse events.

The reconstitution steps shown here are reasonable harm reduction if someone is going to use this regardless. Bacteriostatic water is the correct diluent for storage. Sterile technique matters enormously with any injectable. But the video does not mention sterility of injection site, needle gauge considerations, storage temperature after reconstitution, or what to do if the reconstituted product looks cloudy or particulate. Those omissions are meaningful for a tutorial framed as instructional content.

• TB-500 is not approved for human therapeutic use in Australia or the US.
• The reconstitution technique demonstrated is technically sound.
• Caption claims about healing and inflammation are plausible but extrapolated from animal data.
• The commercial relationship with Alpha Research Australia is disclosed via tag and code.